Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human cytomegalovirus glycoprotein B (gB) is a highly conserved, envelope-associated glycoprotein essential for the entry of human cytomegalovirus (HCMV) into host cells. It acts as the primary viral fusogen, mediating fusion between the viral envelope and host cell membranes. gB is required for initial virion attachment and subsequent stable binding. It also facilitates direct cell-to-cell spread of HCMV. gB elicits strong humoral immune responses, but most anti-gB antibodies are non-neutralizing due to epitope shielding by glycans.
Viral entry inhibition (potential)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human Cytomegalovirus Glycoprotein B (gB).